Sai Life Sciences growth ratios

Per cent unless marked ×
Tap a line for its trendFY26Mar 2026
+29.4%
+55.6%
+73.8%
+105.1%
+88.3%
+14.8%
+16.7%
+62.1%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SAILIFE₹1,395.00

Sai Life Sciences Ltd.

· Pharma & Health
₹ CrorePeersSYNGENEDIVISLABPPLPHARMANHNEULANDLABNATCOPHARMLALPATHLABCOHANCEMcap ₹29,543 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+29.4—
EBITDA Growth—+55.6—
EBIT Growth—+73.8—
Net Income Growth—+105.1—
EPS Growth—+88.3—
Total Assets Growth—+14.8—
Total Equity Growth—+16.7—
Cash from Operations Growth—+62.1—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.